Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency: a Randomised, Open-label Multicentre Trial (IRONMAN)
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Iron isomaltoside 1000 (Primary)
- Indications Heart failure; Iron deficiency anaemia; Left ventricular dysfunction
- Focus Therapeutic Use
- Acronyms IRONMAN
- 13 Dec 2016 Planned End Date changed from 1 Aug 2020 to 1 Feb 2021.
- 13 Dec 2016 Planned primary completion date changed from 1 Aug 2020 to 1 Feb 2021.
- 19 Aug 2016 Accordign to a Pharmacosmos media release, status changed from not yet recruiting to recruiting.